Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kangfuxin and Basic Fibroblast Growth Factor for Donor Site Wound Healing
NCT04234321Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2020
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of trafermin and kangfuxin in wound (3 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Wound healing rate at 3 weeks and Actual healing time at 3 weeks. Status: unknown.
02
Drugs
traferminkangfuxin
03
Conditions
wound
Beyond the preview
Go deeper on NCT04234321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234321.